Amgen Inc. $AMGN Stock: Stillwater Wealth Management Group Decreases Stake

Stillwater Wealth Management Group decreased its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 21.5% during the 3rd quarter, Holdings Channel reports. The firm owned 5,725 shares of the medical research company’s stock after selling 1,572 shares during the period. Amgen comprises about 1.3% of Stillwater Wealth Management Group’s investment portfolio, making the stock its 27th biggest position. Stillwater Wealth Management Group’s holdings in Amgen were worth $2,413,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Wellington Altus USA Inc. boosted its holdings in shares of Amgen by 72.3% in the 2nd quarter. Wellington Altus USA Inc. now owns 81 shares of the medical research company’s stock valued at $28,000 after buying an additional 34 shares during the last quarter. Tower View Wealth Management LLC increased its holdings in Amgen by 331.6% during the first quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company’s stock worth $29,000 after buying an additional 63 shares during the last quarter. Nvwm LLC increased its holdings in Amgen by 412.5% during the third quarter. Nvwm LLC now owns 82 shares of the medical research company’s stock worth $35,000 after buying an additional 66 shares during the last quarter. Security National Bank of Sioux City Iowa IA acquired a new position in Amgen during the second quarter worth $36,000. Finally, Evergreen Advisors LLC acquired a new position in Amgen during the first quarter worth $37,000. Institutional investors own 76.50% of the company’s stock.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Positive Phase 3 Tezspire results: Amgen and AstraZeneca reported that Tezspire delivered statistically significant and clinically meaningful improvements in eosinophilic esophagitis. Results included sustained symptom improvement through 52 weeks and a 69% histologic remission rate, strengthening the drug’s potential as a growth driver if approved for this indication. Tezspire Phase 3 results
• Positive Sentiment: Analyst targets moved higher: Piper Sandler set a $457 price target, while Goldman Sachs raised its target to $481. The revisions indicate continued confidence in Amgen’s earnings outlook and pipeline, with the Goldman target implying additional upside from recent trading levels. Piper Sandler price target Goldman Sachs price target
• Positive Sentiment: Upcoming oncology presentation: Amgen will present data and host an investor webcast during the European Society for Medical Oncology Congress on October 24. New oncology data could provide further evidence that its pipeline and portfolio can support future growth. Amgen ESMO 2026 presentation
• Neutral Sentiment: Improving investment narrative: Recent coverage highlights Amgen’s earnings beat, expanding oncology and rare-disease portfolio, and strong cash generation. The company’s 2026 earnings guidance and dividend provide support, but investors still want evidence that newer products can deliver sustained growth. Amgen earnings investment story
• Negative Sentiment: Valuation and growth concerns remain: Commentary comparing Amgen with Bristol Myers Squibb notes that Amgen offers stronger top-line momentum but trades at a substantially higher valuation. With shares near their 52-week high, investors may require continued clinical and earnings execution to justify further gains. Amgen versus Bristol Myers Squibb

Wall Street Analyst Weigh In

A number of research analysts have recently commented on AMGN shares. Wells Fargo & Company decreased their price objective on shares of Amgen from $435.00 to $430.00 and set an “equal weight” rating for the company in a research report on Monday, October 12th. Canaccord Genuity Group upped their target price on shares of Amgen from $366.00 to $384.00 and gave the company a “hold” rating in a report on Wednesday, August 5th. Piper Sandler upped their target price on shares of Amgen from $427.00 to $457.00 and gave the company an “overweight” rating in a report on Thursday, August 20th. Scotiabank raised their target price on shares of Amgen from $450.00 to $500.00 and gave the company an “outperform” rating in a research note on Monday, September 28th. Finally, Royal Bank Of Canada lifted their price target on Amgen from $400.00 to $430.00 and gave the stock an “outperform” rating in a report on Thursday, October 8th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, sixteen have given a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $388.64.

Insider Activity

In other news, SVP Nancy A. Grygiel sold 2,970 shares of the stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the transaction, the senior vice president owned 7,340 shares in the company, valued at approximately $2,951,854.40. This trade represents a 28.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Rachna Khosla sold 2,000 shares of the stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $412.57, for a total value of $825,140.00. Following the transaction, the senior vice president owned 6,404 shares in the company, valued at $2,642,098.28. The trade was a 23.80% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 6,222 shares of company stock worth $2,540,926. Insiders own 0.85% of the company’s stock.

Amgen Stock Performance

Shares of NASDAQ:AMGN traded down $2.73 on Wednesday, hitting $436.21. The company had a trading volume of 685,921 shares, compared to its average volume of 2,744,948. Amgen Inc. has a 1-year low of $288.00 and a 1-year high of $447.03. The stock has a market cap of $235.83 billion, a price-to-earnings ratio of 27.11, a P/E/G ratio of 3.11 and a beta of 0.41. The stock has a 50 day moving average price of $416.19 and a 200 day moving average price of $376.06. The company has a current ratio of 1.37, a quick ratio of 1.13 and a debt-to-equity ratio of 4.44.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.62 by $0.67. The company had revenue of $10.05 billion during the quarter, compared to analysts’ expectations of $9.43 billion. Amgen had a net margin of 22.95% and a return on equity of 124.14%. Amgen’s quarterly revenue was up 9.5% compared to the same quarter last year. During the same quarter last year, the company posted $6.02 EPS. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. Analysts expect that Amgen Inc. will post 22.94 EPS for the current year.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, September 11th. Investors of record on Friday, August 21st were paid a $2.52 dividend. The ex-dividend date was Friday, August 21st. This represents a $10.08 dividend on an annualized basis and a yield of 2.3%. Amgen’s dividend payout ratio is 62.65%.

About Amgen

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.

The company’s products include biologic and specialty medicines such as Enbrel for inflammatory diseases, Prolia and Evenity for osteoporosis, Xgeva for skeletal-related complications, Repatha for cardiovascular risk reduction, Otezla for inflammatory conditions, Tezspire for severe asthma, Blincyto for certain blood cancers, and Lumakras for specific cancers.

Founded in 1980, Amgen is headquartered in Thousand Oaks, California.